KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Income from Continuing Operations (2016 - 2026)

TherapeuticsMD filings provide 17 years of Income from Continuing Operations readings, the most recent being 103000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 116.19% to 103000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 118000.0, a 105.44% increase, with the full-year FY2025 number at 653000.0, up 71.76% from a year prior.
  • Income from Continuing Operations hit 103000.0 in Q1 2026 for TherapeuticsMD, up from 580000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 48453000.0 in Q4 2022 to a low of 17875000.0 in Q1 2022.
  • Median Income from Continuing Operations over the past 5 years was 809000.0 (2024), compared with a mean of 580529.41.
  • The widest YoY moves for Income from Continuing Operations: up 151.9% in 2025, down 798.8% in 2025.
  • TherapeuticsMD's Income from Continuing Operations stood at 48453000.0 in 2022, then tumbled by 103.27% to 1584000.0 in 2023, then skyrocketed by 105.24% to 83000.0 in 2024, then crashed by 798.8% to 580000.0 in 2025, then skyrocketed by 117.76% to 103000.0 in 2026.
  • The last three reported values for Income from Continuing Operations were 103000.0 (Q1 2026), 580000.0 (Q4 2025), and 50000.0 (Q3 2025) per Business Quant data.